Literature DB >> 23605139

Insight into the binding model of new antagonists of kappa receptor using docking and molecular dynamics simulation.

Shiyuan Hu1, Haijing Yu, Yongjuan Liu, Tian Xue, Huabei Zhang.   

Abstract

PF-4455242 and its analogues represent a new series of kappa opioid selective antagonists that demonstrate high selectivity and potency. We investigated their binding mode to the κ-receptor via docking and molecular dynamics simulations. The ranking of the predicted binding free energies is consistent with experimental results. Detailed binding free energies between antagonists and individual protein residues were calculated, and key residues involved in binding were identified. Deviation of the active site residues was investigated, and the results show that Gln115, Leu135, Tyr139, Trp287 and Tyr313 deviate greatly from the reference structure. Information obtained from molecular modeling studies will aid in the design of potent kappa receptor antagonists.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23605139     DOI: 10.1007/s00894-013-1839-3

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  14 in total

Review 1.  Molecular mechanisms and regulation of opioid receptor signaling.

Authors:  P Y Law; Y H Wong; H H Loh
Journal:  Annu Rev Pharmacol Toxicol       Date:  2000       Impact factor: 13.820

Review 2.  Recent advances in selective opioid receptor agonists and antagonists.

Authors:  Masakatsu Eguchi
Journal:  Med Res Rev       Date:  2004-03       Impact factor: 12.944

3.  Comparative modeling of human kappa opioid receptor and docking analysis with the peptide YFa.

Authors:  Mahesh Chandra Patra; Krishan Kumar; Santosh Pasha; Madhu Chopra
Journal:  J Mol Graph Model       Date:  2011-11-26       Impact factor: 2.518

4.  VMD: visual molecular dynamics.

Authors:  W Humphrey; A Dalke; K Schulten
Journal:  J Mol Graph       Date:  1996-02

5.  Reduced surface: an efficient way to compute molecular surfaces.

Authors:  M F Sanner; A J Olson; J C Spehner
Journal:  Biopolymers       Date:  1996-03       Impact factor: 2.505

6.  Design and discovery of a selective small molecule κ opioid antagonist (2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242).

Authors:  Patrick R Verhoest; Aarti Sawant Basak; Vinod Parikh; Matthew Hayward; Gregory W Kauffman; Vanessa Paradis; Stanton F McHardy; Stafford McLean; Sarah Grimwood; Anne W Schmidt; Michelle Vanase-Frawley; Jodi Freeman; Jeffrey Van Deusen; Loretta Cox; Diane Wong; Spiros Liras
Journal:  J Med Chem       Date:  2011-07-22       Impact factor: 7.446

7.  Psychotomimesis mediated by kappa opiate receptors.

Authors:  A Pfeiffer; V Brantl; A Herz; H M Emrich
Journal:  Science       Date:  1986-08-15       Impact factor: 47.728

8.  The structural basis of agonist-induced activation in constitutively active rhodopsin.

Authors:  Jörg Standfuss; Patricia C Edwards; Aaron D'Antona; Maikel Fransen; Guifu Xie; Daniel D Oprian; Gebhard F X Schertler
Journal:  Nature       Date:  2011-03-09       Impact factor: 49.962

9.  Conformational analysis and automated receptor docking of selective arylacetamide-based kappa-opioid agonists.

Authors:  G Subramanian; M G Paterlini; D L Larson; P S Portoghese; D M Ferguson
Journal:  J Med Chem       Date:  1998-11-19       Impact factor: 7.446

10.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility.

Authors:  Garrett M Morris; Ruth Huey; William Lindstrom; Michel F Sanner; Richard K Belew; David S Goodsell; Arthur J Olson
Journal:  J Comput Chem       Date:  2009-12       Impact factor: 3.376

View more
  1 in total

Review 1.  Mathematical and computational modeling in biology at multiple scales.

Authors:  Jack A Tuszynski; Philip Winter; Diana White; Chih-Yuan Tseng; Kamlesh K Sahu; Francesco Gentile; Ivana Spasevska; Sara Ibrahim Omar; Niloofar Nayebi; Cassandra Dm Churchill; Mariusz Klobukowski; Rabab M Abou El-Magd
Journal:  Theor Biol Med Model       Date:  2014-12-27       Impact factor: 2.432

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.